This year, Olon's Daptomycin celebrates its 10th anniversary—and the API supplier group has announced the doubling of its production to meet and exceed global demand for the active ingredient.
Olon Group announces the construction of a cutting-edge High Potency API suite.
Olon Group, a chemical pharmaceutical group, and the Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering, announced a public-private partnership agreement for a research project on the advanced study of polymorphism and the characterization of the solid state of the molecules of active ingredients.
Olon and The Chemistry Department of Politecnico University Launch a Research Project on Polymorphism and Characterization of API Solid State
As part of its strategy for global growth and the enhancement of internal expertise focusing on biotech, Olon has unveiled its two-year plan for investment in the Settimo Torinese Biotech Center in Italy.
Olon Announces New Investment
MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center in Milan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generics market. With a €10-million investment, the Italian Group has announced the creation of a huge area dedicated entirely to research laboratories to be used to develop API (active pharmaceutical ingredients), manufacturing processes, forming a central research hub and which, integrating with the 7 existing Olon research centers will give rise to an innovative global R&D networking model where the high-level expertise and know-how involved in specific processes, consolidated in the 11 Olon plants worldwide, will be connected, and extensively applied across the Group's entire manufacturing network. The major investment involves the construction of a vast area of laboratories, some of which will focus on furthering the development of new, highly sustainable technologies, including biocatalysis and photochemistry. It will also support significant growth in the R&D team, with up to 50 new researchers hired, bringing the total number of people assigned to research activities to around 350.
MILAN, Feb. 9, 2022 /PRNewswire/ -- Olon announces a new milestone of investments in its high containment manufacturing global platform. The Group, leading international API supplier, will be rolling out an investment of 27 million euros over 2022/2023 totally allocated to the expansion of further internal expertise and capacity of high containment production. This expansion is in line with the long-term business strategy of the Group that entails a grow also expanding internal technology platforms, focusing on HPAPI and on biotech as well.
Olon is delighted to announce a major expansion of its Italian site located in Settimo Torinese, which is a historical asset of the global manufacturing network of the Group and moreover represents a centre of excellence for biotechnological manufacturing. The expansion is a key milestone for the site and a cornerstone of the Company strategy that is fostering the development of its biotechnological platform, both in terms of expertise and production capacity.
Olon S.p.A., an active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, has closed the acquisition of the manufacturing facility in Mahad, India.